Combination chemotherapy for metastatic breast cancer: reaching for the cure
- PMID: 12586790
- DOI: 10.1200/JCO.2003.10.085
Combination chemotherapy for metastatic breast cancer: reaching for the cure
Comment on
-
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).J Clin Oncol. 2003 Feb 15;21(4):588-92. doi: 10.1200/JCO.2003.08.013. J Clin Oncol. 2003. PMID: 12586793 Clinical Trial.
Similar articles
-
Improving adjuvant chemotherapy in breast cancer -- can we get more for less with TACT2?Clin Oncol (R Coll Radiol). 2007 Oct;19(8):593-5. doi: 10.1016/j.clon.2007.06.016. Epub 2007 Aug 13. Clin Oncol (R Coll Radiol). 2007. PMID: 17706405 No abstract available.
-
[The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Chemotherapy: the example of clinical studies].Suppl Tumori. 2004 Jul-Aug;3(4):S77-8. Suppl Tumori. 2004. PMID: 15206220 Review. Italian. No abstract available.
-
Clinical trials referral resource. Adjuvant therapy in breast cancer.Oncology (Williston Park). 1994 Nov;8(11):55, 60, 65. Oncology (Williston Park). 1994. PMID: 7826839 No abstract available.
-
Improved outcomes from dose-dense adjuvant chemotherapy for breast cancer with growth factor support.Curr Hematol Rep. 2003 Nov;2(6):451-2. Curr Hematol Rep. 2003. PMID: 14561387 Clinical Trial. No abstract available.
-
Primary chemotherapy regimens and schedules.Semin Oncol. 1998 Apr;25(2 Suppl 3):25-30. Semin Oncol. 1998. PMID: 9566204 Review. No abstract available.
Cited by
-
Doxorubicin and Iron-doped Mesoporous Silica Nanoparticles for Chemodynamic Therapy and Chemotherapy of Breast Cancer.New J Chem. 2024 Oct 21;48(39):17294-17309. doi: 10.1039/d4nj03184a. Epub 2024 Sep 27. New J Chem. 2024. PMID: 40740313
-
Single agent versus combination chemotherapy for metastatic breast cancer.Cochrane Database Syst Rev. 2009 Apr 15;2009(2):CD003372. doi: 10.1002/14651858.CD003372.pub3. Cochrane Database Syst Rev. 2009. PMID: 19370586 Free PMC article.
-
TME-activatable theranostic nanoplatform with ATP burning capability for tumor sensitization and synergistic therapy.Theranostics. 2020 May 25;10(15):6987-7001. doi: 10.7150/thno.44569. eCollection 2020. Theranostics. 2020. PMID: 32550917 Free PMC article.
-
Addressing Genetic Tumor Heterogeneity, Post-Therapy Metastatic Spread, Cancer Repopulation, and Development of Acquired Tumor Cell Resistance.Cancers (Basel). 2023 Dec 29;16(1):180. doi: 10.3390/cancers16010180. Cancers (Basel). 2023. PMID: 38201607 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical